Hunterase®
Description: Hunterase®, (iduronidase-2-sulfatase) is a recombinant human Enzyme Replacement Therapy (ERT)
Indication: Mucopolysaccharidosis type II (MPS II) or Hunter syndrome
Ownership: Exclusive license to develop and commercialize in Greater China from South Korea’s GC Pharma
Status: Hunterase is designated an orphan drug in the United States and Korea and is marketed in 12 countries. Hunterase was approved for marketing in China in September 2020
Nerlynx®
Description: NERLYNX® (Neratinlib) is a potent irreversible tyrosine kinase inhibitor, that inhibits tumor growth and metastasis through blocking pan-HER family proteins (HER1, HER2, and HER4) and downstream signal transduction
Indication: HER2-positive breast cancer
Ownership: Distribution license from Pierre Fabre in Taiwan
Status: NERLYNX® was approved by US FDA in 2017 and EU in 2018; Approved for marketing in China in 2020
Livmarli®
Description: Livmarli is an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT)
Indication: Cholestatic pruritus in patients with Alagille syndrome
Ownership: Exclusive rights to develop, commercialize, and under certain conditions, manufacture Livmarli in Greater China
Status: Livmarli was approved in the US in 2021, in the EU in 2022, and in Greater China in 2023
